This edited volume presents a thorough exploration of the fundamentals, concepts and methods of nanocrystal development for targeted drug delivery.
In pharmaceutical and biomedical sciences, addressing poor bioavailability is of paramount importance in drug development. Innovative strategies are being employed to enhance the solubility, dissolution rate, and physiochemical properties of Biopharmaceutical Classification System (BCS) II and IV drugs. Drug nanocrystals have emerged as a solution by leveraging the crystalline nature of drugs to address critical challenges. This carrier-free colloidal drug delivery system operates at the nano-size range, where the crystalline drug particle core is enveloped by a stabilizing agent (surfactant/polymer). However, selecting a stabilizer remains a persistent challenge for certain drug molecules.
This book aims to address the critical aspects of nanocrystal technology by covering classification, stabilizer selection criteria, bottom-up and bottom-down preparation, characterization methods, recent advancements, toxicological considerations, regulatory insights, and clinical status of drug nanocrystals. The book advocates the implementation of a quality by design (QbD) and a design of experimentation approach to minimize errors in product optimization and validation for targeted drug delivery systems.
The book comprises of contributions from global experts including renowned formulators, researchers, and academicians ensuring diverse insights and expertise across various specializations. The book is primarily targeted at academic and industrial researchers, Ph.D. and postdoctoral research fellows, formulation scientists, and bio-medical professionals.
